Elicio Therapeutics, Inc. Operating Lease, Payments
Elicio Therapeutics, Inc. (ELTX) reported Operating Lease, Payments of $688.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-13
- Elicio Therapeutics, Inc. operating lease, payments for the quarter ending 2026-06-30 was $347.00K, a 1.76% increase year-over-year.
- Elicio Therapeutics, Inc. operating lease, payments for the quarter ending 2026-03-31 was $341.00K, a 2.10% increase year-over-year.
- Elicio Therapeutics, Inc. operating lease, payments for the quarter ending 2025-12-31 was $338.00K, a 2.11% increase year-over-year.
- Elicio Therapeutics, Inc. operating lease, payments for the quarter ending 2025-09-30 was $337.00K, a 1.81% increase year-over-year.
- Elicio Therapeutics, Inc. operating lease, payments for fiscal 2025 was $1.35M, a 5.40% decline from fiscal 2024.
- Elicio Therapeutics, Inc. operating lease, payments for fiscal 2024 was $1.43M, a 3.41% increase from fiscal 2023.
- Elicio Therapeutics, Inc. operating lease, payments for fiscal 2023 was $1.38M, a 24.77% increase from fiscal 2022.
- Elicio Therapeutics, Inc. operating lease, payments for fiscal 2022 was $1.11M, a 6.19% decline from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 3 month as first filed | Operating Lease, Payments 6 month | Operating Lease, Payments 6 month as first filed | Operating Lease, Payments 9 month | Operating Lease, Payments 9 month as first filed | Operating Lease, Payments 12 month | Operating Lease, Payments 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $347.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $688.00K 10-Q · filed 2026-08-13 | $1.03M derived: sum of 3 quarters · filed 2026-08-13 | $1.36M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $341.00K 10-Q · filed 2026-05-11 | $679.00K derived: sum of 2 quarters · filed 2026-05-11 | $1.02M derived: sum of 3 quarters · filed 2026-05-11 | $1.36M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $338.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $675.00K derived: sum of 2 quarters · filed 2026-03-12 | $1.02M derived: sum of 3 quarters · filed 2026-08-13 | $1.35M 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | $337.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $678.00K derived: sum of 2 quarters · filed 2026-08-13 | $1.01M 10-Q · filed 2025-11-13 | $1.34M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $341.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $675.00K 10-Q · filed 2026-08-13 | $1.01M derived: sum of 3 quarters · filed 2026-08-13 | $1.34M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $334.00K 10-Q · filed 2026-05-11 | $665.00K derived: sum of 2 quarters · filed 2026-05-11 | $996.00K derived: sum of 3 quarters · filed 2026-05-11 | $1.38M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | $331.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $662.00K derived: sum of 2 quarters · filed 2026-03-12 | $1.05M derived: sum of 3 quarters · filed 2026-03-12 | $1.43M 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | $331.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $717.00K derived: sum of 2 quarters · filed 2025-11-13 | $1.10M 10-Q · filed 2025-11-13 | $1.47M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $386.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $765.00K 10-Q · filed 2025-08-07 | $1.14M derived: sum of 3 quarters · filed 2025-08-07 | $1.40M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | $379.00K 10-Q · filed 2025-05-13 | $757.00K derived: sum of 2 quarters · filed 2025-05-13 | $1.02M derived: sum of 3 quarters · filed 2025-05-13 | $1.45M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $378.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $637.00K derived: sum of 2 quarters · filed 2025-03-31 | $1.07M derived: sum of 3 quarters · filed 2025-03-31 | $1.38M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $259.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $690.00K derived: sum of 2 quarters · filed 2024-11-13 | $1.00M 10-Q · filed 2024-11-13 | $1.31M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $431.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $743.00K 10-Q · filed 2024-08-13 | $648.00K 10-Q · filed 2023-08-14 | $1.05M derived: sum of 3 quarters · filed 2024-08-13 | $1.36M derived: sum of 4 quarters · filed 2024-08-13 | |||
| 2023-03-31 | $312.00K 10-Q · filed 2024-05-15 | $57.00K 10-Q · filed 2023-05-10 | $620.00K derived: sum of 2 quarters · filed 2024-05-15 | $929.00K derived: sum of 3 quarters · filed 2024-05-15 | $1.09M derived: sum of 4 quarters · filed 2024-05-15 | |||
| 2022-12-31 | $308.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $617.00K derived: sum of 2 quarters · filed 2024-03-29 | $783.00K derived: sum of 3 quarters · filed 2024-03-29 | $1.11M 10-K · filed 2024-03-29 | $1.29M 10-K · filed 2023-03-17 | |||
| 2022-09-30 | $309.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $475.00K derived: sum of 2 quarters · filed 2023-11-13 | $798.00K 10-Q · filed 2023-11-13 | $966.00K 10-Q · filed 2022-11-14 | $1.12M derived: sum of 4 quarters · filed 2023-11-13 | |||
| 2022-06-30 | $166.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $489.00K 10-Q · filed 2023-08-14 | $644.00K 10-Q · filed 2022-08-15 | $807.00K derived: sum of 3 quarters · filed 2023-08-14 | $1.13M derived: sum of 4 quarters · filed 2023-08-14 | |||
| 2022-03-31 | $323.00K 10-Q · filed 2023-05-10 | $641.00K derived: sum of 2 quarters · filed 2023-05-10 | $959.00K derived: sum of 3 quarters · filed 2023-05-10 | $1.24M derived: sum of 4 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | $318.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $636.00K derived: sum of 2 quarters · filed 2023-03-17 | $912.00K derived: sum of 3 quarters · filed 2023-03-17 | $1.18M 10-K · filed 2023-03-17 | ||||
| 2021-09-30 | $318.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $594.00K derived: sum of 2 quarters · filed 2022-11-14 | $861.00K 10-Q · filed 2022-11-14 | $1.12M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $276.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $543.00K 10-Q · filed 2022-08-15 | $804.00K derived: sum of 3 quarters · filed 2022-08-15 | $996.00K derived: sum of 4 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | $267.00K 10-Q · filed 2022-05-16 | $528.00K derived: sum of 2 quarters · filed 2022-05-16 | $720.00K derived: sum of 3 quarters · filed 2022-05-16 | $1.05M derived: sum of 4 quarters · filed 2022-05-16 | ||||
| 2020-12-31 | $261.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $453.00K derived: sum of 2 quarters · filed 2022-03-30 | $785.00K derived: sum of 3 quarters · filed 2022-03-30 | $1.08M 10-K · filed 2022-03-30 | ||||
| 2020-09-30 | $192.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $524.00K derived: sum of 2 quarters · filed 2021-11-12 | $820.00K 10-Q · filed 2021-11-12 | |||||
| 2020-06-30 | $332.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $628.00K 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | $296.00K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |